共查询到20条相似文献,搜索用时 119 毫秒
1.
2.
竞争性内源RNA (competing endogenous RNA, ceRNA)作为生物标志物和潜在的治疗靶点,在探究肿瘤的发病机制中,表现出了巨大的研究价值和临床应用前景。本文对乳腺癌ceRNA网络进行了系统的分析,首先通过差异分析获得差异miRNA、mRNA和lncRNA,其次利用网络的边聚集系数(edge clustering coefficient,ECC)和皮尔逊相关系数(Pearson correlation coefficient, PCC)计算ceRNA网络节点的权重,最后采用基于随机森林的逐步特征选择(stepwise feature selection based on random forest, SFS-RF)方法筛选出一组可作为乳腺癌生物标志物的RNA——LINC00466、CHL1-AS2和LINC00337,并利用GEO数据库验证了该组RNA对乳腺癌样本的识别情况。此外,通过GO和KEGG通路富集分析探索了该组RNA在乳腺癌中的生物学功能。结果显示:这些RNA作为生物标志物,在识别乳腺癌样本方面具有高精度和高效率等特性,在乳腺肿瘤细胞的增殖及遗传物质的合成等过程中具有重要生物学意义。 相似文献
3.
李轶 《中国生物化学与分子生物学报》2021,37(5):556-563
长非编码RNA(long non-coding RNAs, lncRNAs)是一类转录本长度大于200个核苷酸,不具有蛋白质编码功能的非编码RNA(non-coding RNA, ncRNA)。人类基因组中,ncRNA基因占比超过90%,数量远大于蛋白质编码基因。作为生物大分子,lncRNA具有特定的初级和高级结构,在基因表达调控等生物学进程中发挥着特有的功能。lncRNA数量多,结构各异,因此鉴定和表征新的lncRNA,探索其结构和功能,是当前基因研究领域的热点之一。在临床疾病机制研究中,大量结果表明,lncRNA与临床疾病发生发展,特别是肿瘤的发生发展具有密切的相关性。伴随着后基因组学时代基因鉴定和功能探索方法的不断进步,探索lncRNA在疾病发生中的功能及表达变化,深入解锁lncRNA在疾病发生中涉及的分子机制,将为疾病早期预防、诊断和预后提供有效参考。基于以上的研究大背景,本文对lncRNA的定义、基因鉴定的策略和方法,高级结构检测及其对应的生物学功能,以及lncRNA的分类进行了阐述;另一方面,基于lncRNA与肿瘤发生发展的密切关系,本文以经典抑癌基因p53为切入点,对多种p53相关的lncRNA在结直肠癌(colorectal cancer, CRC)发生发展中的作用进行了归纳小结,阐述了lncRNA在结直肠癌中的表达变化、涉及的分子互作机制和信号通路,对其作为分子标志物在临床中的应用潜力进行了评估。我们乐观地认为,作为生物分子标志物,lncRNA将为包括癌症在内的疾病治疗提供全新、精准和个性化的分子靶点。 相似文献
4.
长链非编码RNA(long noncoding RNAs,lncRNAs)是一类长度大于200个核苷酸的非蛋白质编码RNA。绝大多数lncRNA来源于核基因组。但近年研究发现,一些lncRNA是由线粒体基因组编码、转录而成,或定位于线粒体。本文将从线粒体lncRNA的发现与主要种类、线粒体lncRNA的加工和结构,以及它们的功能和应用等几个方面,对线粒体lncRNA进行阐述。线粒体lncRNA可能成为心血管疾病或肿瘤诊断的生物标志物,或在调控线粒体基因表达等方面发挥重要功能。 相似文献
5.
6.
长链非编码RNA(Long non-coding RNAs,lncRNAs)是一类广泛存在于真核生物中,长度大于200个核苷酸、无蛋白编码功能,具有调控基因转录后表达的RNA转录本。新近研究表明,lncRNA在多种生物途径中起着重要调节作用。生物信息学由生物、数学、计算机科学,统计学等多学科交叉产生,能从全局和系统水平对大数据信息进行深入挖掘与分析。采用生物信息学方法预测与分析lncRNA是当前发现和鉴定植物lncRNA的重要策略之一。本文梳理和总结了近年来采用生物信息学预测植物lncRNA及其靶基因的方法策略,以期为今后深入认知植物lncRNA在植物的生长发育过程、抗逆境胁迫及系统进化等过程中的作用研究提供一定参考。 相似文献
7.
长链非编码RNA(long non-coding RNA, lncRNA)是一类转录本长度超过200nt、不编码蛋白质的RNA。近年来,随着染色质构象捕获及转录组测序等技术的发展,lncRNA与染色质构象间的关系越来越受到重视。多项研究表明,lncRNA在基因调控网络中具有重要的作用,可通过影响细胞核高级结构的动态变化来调控真核基因的表达。因其广泛的基因调控功能及在肿瘤发生过程中的重要作用,lncRNA被认为是未来肿瘤临床诊断和预后判定的新型标志物之一。本文旨在介绍lncRNA改变细胞核高级结构从而调控关键基因表达的分子机制,并详细介绍lncRNA在肿瘤治疗中的临床意义。 相似文献
8.
非编码RNA(non-coding RNA,ncRNA)是不具备编码蛋白质功能的基因组转录产物。研究逐步发现,ncRNA的表达失调与人类疾病的发生密切相关。由于ncRNA表达失调具有组织特异性,同时,在人类组织和体液中可被便捷、稳定地检测,许多研究开始关注ncRNA作为临床疾病诊断标志物的应用潜能。现主要围绕微小分子RNA(miRNA)和长非编码RNA(lncRNA)在恶性肿瘤、自身免疫性疾病及神经系统疾病诊断中的作用进行综述;同时,也从ncRNA失调与疾病发生的相互关系的角度展示了ncRNA相较其他生物分子作为疾病诊断标志物的优势。 相似文献
9.
胃癌(gastric cancer,GC)是我国最常见的恶性肿瘤之一,严重危害人类健康。胃癌发病机制复杂,缺乏特异性预后生物标志物。长链非编码RNA (long non-coding RNA,lncRNA)可作为竞争性内源RNA (competing endogenous RNA,ceRNA),影响microRNA (miRNA)与mRNA的结合,从而影响胃癌的发生、发展。基于TCGA和GEO数据库的转录组数据,筛选GC 中差异表达的 lncRNAs,并构建基于 6 条 lncRNAs(HAGLROS、TMEM92-AS1、LINC01745、HOXC-AS3、SEMA3B-AS1、FEZF1-AS 1)的lncRNA-miRNA-mRNA网络。网络核心基因的KEGG/GO富集和蛋白质互作分析结果显示,lncRNA可能通过miRNA海绵吸附作用,调控胃癌的发生、发展与转移。AC011352.1、AC087636.1、AC093627.1、GAS1RR与胃癌患者的预后相关性具有统计学意义(P<0.05),并可能成为胃癌患者潜在的预后生物标志物。 相似文献
10.
液体活检是一种基于分析体液样本中的生物标志物来诊断疾病、监测疾病进展和评估疗效的非侵入性的新型微创诊断技术。液体活检主要包括探查和检测循环肿瘤细胞、ctDNA、非编码RNAs和细胞外囊泡等。非编码RNA之前被认为是一类无功能的RNA,但近年来研究表明它们在肿瘤的发病机制中扮演着重要的角色。它们构成了基因调控的一个重要层面,其表达水平在多种癌种中呈现失调势态,这提示了它们作为肿瘤生物学标志物的临床应用潜力。飞速发展的高通量测序技术使得在泛癌领域建立非编码RNA表达谱的分子表征成为可能。该文系统阐述了非编码RNA作为非侵入性肿瘤标志物的研究进展,评估了其作为肿瘤生物标志物的适用性,同时总结了近期的检测技术突破对肿瘤分子标志物发展的影响。 相似文献
11.
Gerardo Botti Antonio Giordano Florinda Feroce Anna Rosaria De Chiara Monica Cantile 《Journal of cellular physiology》2019,234(11):19249-19255
Noncoding RNAs (ncRNAs) identify a large family of RNAs that do not encode proteins and represent an important group of tumor biomarkers, directly involved in the process of tumor pathogenesis and progression. Many of them have also been identified in biological fluids of patients with cancer, especially blood, suggesting their role as an emerging class of circulating biomarkers. Many ncRNAs, both miRNAs and lncRNAs, are deregulated in sarcoma tissues, with the most consistent data in osteosarcomas. In patients with osteosarcoma, the role of ncRNAs as circulating biomarkers is taking enormous value, above all for their ability to vary expression levels during disease progression and in response to therapy. In this mini-review, we summarize the main studies supporting the role of circulating ncRNAs in monitoring disease status in patients with osteosarcoma. 相似文献
12.
Objective: Increasing the efficiency of early diagnosis using noninvasive biomarkers is crucial for enhancing the survival rate of lung cancer patients. We explore the differential expression of non-small cell lung cancer (NSCLC)-related long noncoding RNAs (lncRNAs) in urinary exosomes in NSCLC patients and normal controls to diagnose lung cancer.Methods: A differential expression analysis between NSCLC patients and healthy controls was performed using microarrays. Gene ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were used to predict potential functions of lncRNAs in NSCLC. quantitative real-time PCR (QT-PCR) was used to verify microarray results.Results: A total of 640 lncRNAs (70 up- and 570 down-regulated) were differentially expressed in NSCLC patients in comparison to healthy controls. Six lncRNAs were detected by QT-PCR. GO term and KEGG pathway analyses showed that differential lncRNAs were enriched in cellular component organization or biogenesis, as well as other biological processes and signaling pathways, such as the PI3K-AKT, FOXO, p53, and fatty acid biosynthesis.Conclusions: The differential lncRNAs in urinary exosomes are potential diagnostic biomarkers of NSCLC. The lncRNAs enriched in specific pathways may be associated with tumor cell proliferation, tumor cell apoptosis, and the cell cycle involved in the pathogenesis of NSCLC. 相似文献
13.
Mei‐Li Zheng Xiao‐Yan Liu Rui‐Juan Han Wen Yuan Kai Sun Jiu‐Chang Zhong Xin‐Chun Yang 《Journal of cellular and molecular medicine》2020,24(16):9388-9396
Exosomes are attracting considerable interest in the cardiovascular field as the wide range of their functions is recognized in acute myocardial infarction (AMI). However, the regulatory role of exosomal long non‐coding RNAs (lncRNAs) in AMI remains largely unclear. Exosomes were isolated from the plasma of AMI patients and controls, and the sequencing profiles and twice qRT‐PCR validations of exosomal lncRNAs were performed. A total of 518 differentially expressed lncRNAs were detected over two‐fold change, and 6 kinds of lncRNAs were strikingly elevated in AMI patients with top fold change and were selected to perform subsequent validation. In the two validations, lncRNAs ENST00000556899.1 and ENST00000575985.1 were significantly up‐regulated in AMI patients compared with controls. ROC curve analysis revealed that circulating exosomal lncRNAs ENST00000556899.1 and ENST00000575985.1 yielded the area under the curve values of 0.661 and 0.751 for AMI, respectively. Moreover, ENST00000575985.1 showed more significant relationship with clinical parameters, including inflammatory biomarkers, prognostic indicators and myocardial damage markers. Multivariate logistic model exhibited positive association of ENST00000575985.1 with the risk of heart failure in AMI patients. In summary, our data demonstrated that circulating exosomal lncRNAs ENST00000556899.1 and ENST00000575985.1 are elevated in patients with AMI, functioning as potential biomarkers for predicting the prognosis of pateints with AMI. 相似文献
14.
Zheng Li Xingye Li Chao Jiang Wenwei Qian Gary Tse Matthew T.V. Chan William K.K. Wu 《Cell proliferation》2018,51(1)
Rheumatoid arthritis, a disabling autoimmune disease, is associated with altered gene expression in circulating immune cells and synovial tissues. Accumulating evidence has suggested that long non‐coding RNAs (lncRNAs), which modulate gene expression through multiple mechanisms, are important molecules involved in immune and inflammatory pathways. Importantly, many studies have reported that lncRNAs can be utilized as biomarkers for disease diagnosis and prognostication. Recently, dysregulation of lncRNAs in rheumatoid arthritis and other autoimmune diseases has been revealed. Experimental studies also confirmed their crosstalk with matrix metalloproteinases, nuclear factor‐κB signalling and T‐cell response pertinent to autoimmunity and inflammation. Circulating lncRNAs, such as HOTAIR, differentiated patients with rheumatoid arthritis from healthy subjects. Taken together, lncRNAs are good candidates as biomarkers and therapeutic targets in rheumatoid arthritis. Further investigation on in vivo delivery of these regulatory molecules and large‐cohort validation of their clinical applicability may be useful. 相似文献
15.
Polyglutamine (polyQ) diseases are characterized by trinucleotide repeat amplifications within genes, thus resulting in the formation of polyQ peptides, selective neuronal degeneration and possibly death due to neurodegenerative diseases (NDDs). Long non-coding RNAs (lncRNAs), which exceed 200 nucleotides in length, have been shown to play important roles in several pathological processes of NDDs, including polyQ diseases. Some lncRNAs have been consistently identified to be specific to polyQ diseases, and circulating lncRNAs are among the most promising novel candidates in the search for non-invasive biomarkers for the diagnosis and prognosis of polyQ diseases. In this review, we describe the emerging roles of lncRNAs in polyQ diseases and provide an overview of the general biology of lncRNAs, their implications in pathophysiology and their potential roles as future biomarkers and applications for therapy. 相似文献
16.
Encieh Delshad Fatemeh T. Shamsabadi Shabbou Bahramian Fatemeh Mehravar Hossein Maghsoudi 《Journal of biomolecular structure & dynamics》2020,38(7):1954-1962
AbstractGastric cancer (GC) is the second leading cause of cancer-related deaths in the world. Due to the shortage of adequate symptoms in the early stages, it is diagnosed when the tumor has spread to distant organs. Early recognition of GC enhances the chance of successful treatment. Molecular mechanisms of GC are still poorly understood. LncRNAs are emerging as new players in cancer in both oncogene and tumor suppressor roles. High-throughput technologies such as RNA-Seq, have revealed thousands of lncRNAs which are dysregulated in GC. In this study, we retrieved lncRNAs obtained by High-throughput technologies from OncoLnc database. Consequently, retrieved lncRNAs were compared in literature-based databases including PubMed. As a result, two lists, including experimentally validated lncRNAs and predicted lncRNAs were provided. We found 43 predicted lncRNAs that had not been experimentally validated in GC, so far. Further Bioinformatics analyses were performed to obtain the expression profile of predicted lncRNAs in tumor and normal tissues. Also, the roles and targets of predicted lncRNAs in GC were identified by related databases. Finally, using the GEPIA database was reviewed the significant relationship of predicted lncRNAs with the survival of GC patients. By recognizing the lncRNAs involved in initiation and progression of GC, they may be considered as potential biomarkers in the GC early diagnosis or targeted treatment and lead to novel therapeutic strategies. Communicated by Ramaswamy H. Sarma 相似文献
17.
The early detection of lung cancer is a major clinical challenge. Long noncoding RNAs (lncRNAs) have important functions in tumorigenesis. Plasma lncRNAs directly released from primary tumors or the circulating cancer cells might provide cell-free cancer biomarkers. The objective of this study was to investigate whether the lncRNAs could be used as plasma biomarkers for early-stage lung cancer. By using droplet digital polymerase chain reaction, we determined the diagnostic performance of 26 lung cancer–associated lncRNAs in plasma of a development cohort of 63 lung cancer patients and 33 cancer-free individuals, and a validation cohort of 39 lung cancer patients and 28 controls. In the development cohort, 7 of the 26 lncRNAs were reliably measured in plasma. Two (SNHG1 and RMRP) displayed a considerably high plasma level in lung cancer patients vs. cancer-free controls (all P?<?.001). Combined use of the plasma lncRNAs as a biomarker signature produced 84.13% sensitivity and 87.88% specificity for diagnosis of lung cancer, independent of stage and histological type of lung tumor, and patients' age and sex (all P?>?.05). The diagnostic value of the plasma lncRNA signature for lung cancer early detection was confirmed in the validation cohort. The plasma lncRNA signature may provide a potential blood-based assay for diagnosing lung cancer at the early stage. Nevertheless, a prospective study is warranted to validate its clinical value. 相似文献
18.
19.
长链非编码RNA(lncRNA)是一类长度大于200个核苷酸、不具有蛋白质编码功能的转录本.许多研究已经证实,lncRNA在多种类型的肿瘤中存在异常表达,在肿瘤发生、发展中起着致癌或抑癌作用,是肿瘤发生的一类重要因素.分析lncRNA的方法有表达芯片技术、实时定量逆转录-聚合酶链反应技术、原位杂交技术和RNA深度测序技术等.目前已在组织、血液、尿液和唾液等检材中检测到肿瘤相关lncRNA.因此,lncRNA有望成为新型肿瘤标志物应用于肿瘤诊断和预后判定. 相似文献
20.
Mohammad Sarfi Maryam Abbastabar Ehsan Khalili 《Journal of cellular physiology》2019,234(10):16971-16986
Cancer diagnosis have mainly relied on the incorporation of molecular biomarkers as part of routine diagnostic tool. The molecular alteration ranges from those involving DNA, RNA, noncoding RNAs (microRNAs and long noncoding RNAs [lncRNAs]) and proteins. lncRNAs are recently discovered noncoding endogenous RNAs that critically regulates the development, invasion, and metastasis of cancer cells. They are dysregulated in different types of malignancies and have the potential to serve as diagnostic markers for cancer. The expression of noncoding RNAs is altered following many diseases, and besides, some of them can be secreted from the cells into the circulation following the apoptotic and necrotic cell death. These secreted noncoding RNAs are known as cell free RNA. These RNAs can be secreted from the cell through the apoptotic body, extracellular vesicles including microvesicle and exosome, and bind to proteins. Since, lncRNAs display high organ and cell specificity, can be found in the blood, urine, tumor tissue, or other tissues or bodily fluids of some patients with cancer, this review summarizes the most significant and up-to-date findings of research on lncRNAs involvement in different cancers, focusing on the potential of cancer-related lncRNAs as biomarkers for diagnosis, prognosis, and therapy. 相似文献